Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
A chance discovery at a U.K. hospital led to the synthesis of an antibody that could prevent blood clots without causing excessive bleeding. Index Ventures created and funded single-asset company XO1 to conduct first-in-man tests on the compound by 2015.
You may also be interested in...
Medicxi Ventures Launches With €210 Million Fund
Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its "asset-centric" approach to investing.
Deal Watch: Valeant Increases Bid, Wrests Salix Away From Endo
Janssen moves into a new generation of anticoagulation with X01 buyout. Lilly obtains Phase II-ready autoimmune candidate from South Korea’s Hanmi, which partnered a cancer compound with Spectrum just a week earlier, while AstraZeneca finds a commercialization partner for Movantik in Japan’s Daiichi Sankyo.
Financings Of The Fortnight: Corporate Venture Plays Increased Role In Series A Financings
More than one-quarter of biopharma or diagnostic start-ups that raised A rounds in the past 18 months had participation by one or more corporate venture arms. Plus news on recent financings by Esperion Therapeutics, XO1, PTC Therapeutics and Valeant.